Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
Growth factor-induced SMC proliferation is inhibited by SR33805 (0.01-10 µM; 3 d) in a dose-dependent manner (0.2050<0.46 µM) [3]. Without altering the Ca2+ transient amplitude, SR33805 (10 µM; 10 min) recovers the cell shortening that was changed after a myocardial infarction (MI) [2]. SR33805 (10 µM) inhibits recombinant PKA activity [2].
|
---|---|
ln Vivo |
Rats with MI who receive a single intraperitoneal injection of SR33805 (20 mg/kg) show improved fractional shortening and end-systolic strain [2]. Pigs treated with SR33805 (5 mg/kg/day; orally for 38 days) have significantly less intimal hyperplasia [3].
|
Cell Assay |
Cell Viability Assay [3]
Cell Types: Smooth Muscle Cells (SMC) Tested Concentrations: 0.01, 0.1, 1, 10 µM Incubation Duration: 3 days Experimental Results: Inhibited FCS, bFGF and PDGF-induced porcine proliferation in a dose-dependent manner IC50 of SMC respectively are 0.26±0.08, 0.46±0.1 and 0.20±0.04 µM. |
Animal Protocol |
Animal/Disease Models: Male Wistar rats (5 weeks) underwent coronary artery ligation [2]
Doses: 0.2, 2, 20 mg/kg Route of Administration: single intraperitoneal (ip) injection Experimental Results: End-systolic strain (ESS) and fractional shortening were significant Increases (FS) were approximately +38% and +26%, respectively, at the 20 mg/kg dose. Does not affect other shrinkage parameters. |
References |
[1]. Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5.
[2]. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9. [3]. Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154(2): 301-8. |
Molecular Formula |
C32H40N2O5
|
---|---|
Molecular Weight |
564.7354
|
Exact Mass |
564.27
|
Elemental Analysis |
C, 68.06; H, 7.14; N, 4.96; O, 14.16; S, 5.68
|
CAS # |
121345-64-0
|
Related CAS # |
121346-33-6 (oxalate);121345-64-0;
|
Appearance |
Solid powder
|
SMILES |
O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C3=C(C(C)C)N(C)C4=C3C=CC=C4)=O
|
InChi Key |
OGLMUIRZIMTHMN-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C32H40N2O5S/c1-23(2)31-32(27-10-7-8-11-28(27)34(31)4)40(35,36)26-15-13-25(14-16-26)39-21-9-19-33(3)20-18-24-12-17-29(37-5)30(22-24)38-6/h7-8,10-17,22-23H,9,18-21H2,1-6H3
|
Chemical Name |
N-(3,4-dimethoxyphenethyl)-3-(4-((2-isopropyl-1-methyl-1H-indol-3-yl)sulfonyl)phenoxy)-N-methylpropan-1-amine
|
Synonyms |
SR33805 SR-33805 SR 33805
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~177.07 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7707 mL | 8.8536 mL | 17.7073 mL | |
5 mM | 0.3541 mL | 1.7707 mL | 3.5415 mL | |
10 mM | 0.1771 mL | 0.8854 mL | 1.7707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.